Abstract
Annual screening for microalbuminuria will allow the identification of patients with nephropathy at a point very early in its course. Improving glycemic control, aggressive antihypertensive treatment, and the use of ACE inhibitors or ARBs will slow the rate of progression of nephropathy. In addition, protein restriction and other treatment modalities such as phosphate lowering may have benefits in selected patients.
Cite
CITATION STYLE
Molitch, M. E., DeFronzo, R. A., Franz, M. J., Keane, W. F., Mogensen, C. E., Parving, H. H., & Steffes, M. W. (2003, January 1). Diabetic nephropathy. Diabetes Care. American Diabetes Association Inc. https://doi.org/10.2337/diacare.26.2007.s94
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.